Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TriSalus Life Sciences (TLSI) Research & Development (2022 - 2025)

TriSalus Life Sciences (TLSI) has 4 years of Research & Development data on record, last reported at $2.6 million in Q4 2025.

  • For Q4 2025, Research & Development fell 13.15% year-over-year to $2.6 million; the TTM value through Dec 2025 reached $15.0 million, down 15.39%, while the annual FY2025 figure was $15.0 million, 15.39% down from the prior year.
  • Research & Development reached $2.6 million in Q4 2025 per TLSI's latest filing, down from $5.2 million in the prior quarter.
  • Across five years, Research & Development topped out at $9.6 million in Q3 2023 and bottomed at $2.6 million in Q4 2025.
  • Average Research & Development over 4 years is $5.3 million, with a median of $5.2 million recorded in 2025.
  • Peak YoY movement for Research & Development: increased 23.97% in 2023, then crashed 61.91% in 2024.
  • A 4-year view of Research & Development shows it stood at $6.3 million in 2022, then rose by 23.97% to $7.8 million in 2023, then plummeted by 61.91% to $3.0 million in 2024, then fell by 13.15% to $2.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $2.6 million in Q4 2025, $5.2 million in Q3 2025, and $3.9 million in Q2 2025.